PMID- 33951700
OWN - NLM
STAT- MEDLINE
DCOM- 20211208
LR  - 20230911
IS  - 1533-4023 (Electronic)
IS  - 0160-2446 (Linking)
VI  - 77
IP  - 5
DP  - 2021 May 1
TI  - Efficacy and Safety of LCZ696 for Short-term Management of Essential Hypertension 
      Compared With ARBs: A Meta-analysis of Randomized Controlled Trials.
PG  - 650-659
LID - 10.1097/FJC.0000000000001001 [doi]
AB  - Whether LCZ696 (neprilysin inhibitor + valsartan) has greater advantages of blood 
      pressure (BP) lowering than angiotensin II type 1 receptor blockers (ARBs) is 
      unclear. To provide more detailed information about the benefits of LCZ696, we 
      conducted a meta-analysis to evaluate the efficacy and safety of LCZ696 for 
      short-term management of hypertension compared with ARBs. We searched PubMed, 
      EMBASE, the Cochrane Library, and ClinicalTrials.gov, using relevant keywords. We 
      used a random or fixed effects model to calculate the weighted mean difference 
      (WMD) of changes in BP and the risk ratio (RR) for BP control rates and adverse 
      events (AEs). In this meta-analysis, 9 studies were incorporated. Compared with 
      ARBs, LCZ696 revealed a significant reduction in mean sitting systolic BP [msSBP; 
      WMD -4.79 mm Hg; 95% confidence interval (CI): -5.46 to -4.11 mm Hg], mean 
      sitting diastolic BP (msDBP; WMD -2.12 mm Hg; 95% CI: -2.53 to -1.71 mm Hg), mean 
      sitting pulse pressure (msPP; WMD -2.79 mm Hg; 95% CI: -3.52 to -2.07 mm Hg), and 
      mean ambulatory pulse pressure (maPP; WMD -2.96 mm Hg; 95% CI: -3.35 to -2.57 mm 
      Hg). LCZ696 had a higher BP control rate than ARBs (OR = 1.55; 95% CI: 1.39 to 
      1.73). There was no significant difference between LCZ696 and ARBs in the 
      incidence of AEs (RR = 1.10; 95% CI: 0.96 to 1.25) and discontinuations because 
      of AEs (RR = 0.97; 95% CI: 0.54 to 1.32). Overall, in short-term treatment, 
      LCZ696 has greater advantages of antihypertensive efficacy and the safety is not 
      inferior to ARBs. Further long-term studies are required to rule out the 
      potential risks of beta amyloid accumulation and the potential for Alzheimer's 
      disease.
CI  - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Yang, Shuai
AU  - Yang S
AD  - Department of Cardiovascular Medicine, Second Affiliated Hospital of Nanchang 
      University, Nanchang, China; and.
AD  - Medical Center of the Graduate School, Nanchang University, Nanchang, China.
FAU - Zhang, Hongzhou
AU  - Zhang H
AD  - Department of Cardiovascular Medicine, Second Affiliated Hospital of Nanchang 
      University, Nanchang, China; and.
AD  - Medical Center of the Graduate School, Nanchang University, Nanchang, China.
FAU - Yang, Pingping
AU  - Yang P
AD  - Department of Cardiovascular Medicine, Second Affiliated Hospital of Nanchang 
      University, Nanchang, China; and.
AD  - Medical Center of the Graduate School, Nanchang University, Nanchang, China.
FAU - Wang, Chenxi
AU  - Wang C
AD  - Department of Cardiovascular Medicine, Second Affiliated Hospital of Nanchang 
      University, Nanchang, China; and.
AD  - Medical Center of the Graduate School, Nanchang University, Nanchang, China.
FAU - Wu, Qinghua
AU  - Wu Q
AD  - Department of Cardiovascular Medicine, Second Affiliated Hospital of Nanchang 
      University, Nanchang, China; and.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Aminobutyrates)
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Drug Combinations)
RN  - 0 (Protease Inhibitors)
RN  - 80M03YXJ7I (Valsartan)
RN  - EC 3.4.24.11 (Neprilysin)
RN  - WB8FT61183 (sacubitril and valsartan sodium hydrate drug combination)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aminobutyrates/adverse effects/*therapeutic use
MH  - Angiotensin Receptor Antagonists/adverse effects/*therapeutic use
MH  - Biphenyl Compounds/adverse effects/*therapeutic use
MH  - Blood Pressure/*drug effects
MH  - Drug Combinations
MH  - Essential Hypertension/diagnosis/*drug therapy/physiopathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neprilysin/antagonists & inhibitors
MH  - Protease Inhibitors/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
MH  - Valsartan/adverse effects/*therapeutic use
MH  - Young Adult
COIS- The authors report no conflicts of interest.
EDAT- 2021/05/06 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/05/05 20:19
PHST- 2020/11/16 00:00 [received]
PHST- 2021/02/10 00:00 [accepted]
PHST- 2021/05/06 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/05/05 20:19 [entrez]
AID - 00005344-202105000-00015 [pii]
AID - 10.1097/FJC.0000000000001001 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 2021 May 1;77(5):650-659. doi: 
      10.1097/FJC.0000000000001001.